New Trends in Cannabis Potency in USA and Europe During the Last Decade (2008-2017)

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2019 Jan 24

PMID 30671616

Citations 181

Authors

Suman Chandra

Mohamed M Radwan

Chandrani G Majumdar

James C Church

Tom P Freeman

Mahmoud A ElSohly

Affiliations

Soon will be listed here.

Abstract

Through the potency monitoring program at the University of Mississippi supported by National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations have been analyzed over the last decade, using a validated GC/FID method. The samples are classified as sinsemilla, marijuana, ditchweed, hashish, and hash oil (now referred to as cannabis concentrate). The number of samples received over the last 5 years has decreased dramatically due to the legalization of marijuana either for medical or for recreational purposes in many US states. The results showed that the mean Δ-THC concentration has increased dramatically over the last 10 years, from 8.9% in 2008 to 17.1% in 2017. The mean Δ-THC:CBD ratio also rose substantially from 23 in 2008 to 104 in 2017. There was also marked increase in the proportion of hash oil samples (concentrates) seized (0.5-4.7%) and their mean Δ-THC concentration (6.7-55.7%) from 2008 to 2017. Other potency monitoring programs are also present in several European countries such as The Netherlands, United Kingdom, France, and Italy. These programs have also documented increases in Δ-THC concentrations and Δ-THC:CBD ratios in cannabis. These trends in the last decade suggest that cannabis is becoming an increasingly harmful product in the USA and Europe.

Citing Articles

Cannabis use characteristics and associations with problematic use outcomes, quitting-related factors, and mental health among US young adults.

Berg C, LoParco C, Romm K, Cui Y, McCready D, Wang Y Subst Abuse Treat Prev Policy. 2025; 20(1):1.

PMID: 39799369 PMC: 11725203. DOI: 10.1186/s13011-025-00634-0.

Examining the Relationship Between Cannabis Use and Mood, Anxiety, and Psychotic Symptoms in Psychiatric Patients with Severe Concurrent Mental Health and Substance Use Disorders Before and After Recreational Cannabis Legalization in Canada.

Thiessen K, Schutz C Cannabis. 2025; 7(3):90-105.

PMID: 39781555 PMC: 11705035. DOI: 10.26828/cannabis/2024/000258.

Research and Clinical Practice Involving the Use of Products, with Emphasis on Cannabidiol: A Narrative Review.

Simei J, Souza J, Pedrazzi J, Guimaraes F, Campos A, Zuardi A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770486 PMC: 11677192. DOI: 10.3390/ph17121644.

Risk thresholds for the frequency of cannabis use during pregnancy and adverse neonatal outcomes: protocol for a systematic review and dose-response meta-analysis.

Robinson T, Fischer B, Hautala R, Bertram M, Ali M, Farrokhyar F Syst Rev. 2024; 13(1):307.

PMID: 39702238 PMC: 11657691. DOI: 10.1186/s13643-024-02718-7.

Evaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay.

Watts D, Lebel C, Chaput K, Giesbrecht G, Dewsnap K, Baglot S JAACAP Open. 2024; 2(4):250-262.

PMID: 39697398 PMC: 11650681. DOI: 10.1016/j.jaacop.2024.03.004.

References

ElSohly M, Ross S, Mehmedic Z, Arafat R, Yi B, Banahan 3rd B . Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000; 45(1):24-30. View

DuToit B . Man and cannabis in Africa: a study of diffusion. Afr Econ Hist. 1976; (1):17-35. View

Kalant H . Medicinal use of cannabis: history and current status. Pain Res Manag. 2002; 6(2):80-91. DOI: 10.1155/2001/469629. View

Pijlman F, Rigter S, Hoek J, Goldschmidt H, Niesink R . Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol. 2005; 10(2):171-80. DOI: 10.1080/13556210500123217. View

Ben Amar M . Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006; 105(1-2):1-25. DOI: 10.1016/j.jep.2006.02.001. View

Zuardi A . History of cannabis as a medicine: a review. Braz J Psychiatry. 2006; 28(2):153-7. DOI: 10.1590/s1516-44462006000200015. View

Russo E . History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007; 4(8):1614-48. DOI: 10.1002/cbdv.200790144. View

Potter D, Clark P, Brown M . Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008; 53(1):90-4. DOI: 10.1111/j.1556-4029.2007.00603.x. View

Hanus L . Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2008; 29(2):213-71. DOI: 10.1002/med.20135. View

10.

Aggarwal S, Carter G, Sullivan M, Zumbrunnen C, Morrill R, Mayer J . Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009; 5(3):153-68. DOI: 10.5055/jom.2009.0016. View

11.

Bhattacharyya S, Morrison P, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T . Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2009; 35(3):764-74. PMC: 3055598. DOI: 10.1038/npp.2009.184. View

12.

Morgan C, Freeman T, Schafer G, Curran H . Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010; 35(9):1879-85. PMC: 2906701. DOI: 10.1038/npp.2010.58. View

13.

Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel A . Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010; 55(5):1209-17. DOI: 10.1111/j.1556-4029.2010.01441.x. View

14.

Hillig K, Mahlberg P . A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2011; 91(6):966-75. DOI: 10.3732/ajb.91.6.966. View

15.

Cascini F, Aiello C, Di Tanna G . Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2011; 5(1):32-40. DOI: 10.2174/1874473711205010032. View

16.

Englund A, Morrison P, Nottage J, Hague D, Kane F, Bonaccorso S . Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2012; 27(1):19-27. DOI: 10.1177/0269881112460109. View

17.

Chouvy P, Afsahi K . Hashish revival in Morocco. Int J Drug Policy. 2014; 25(3):416-23. DOI: 10.1016/j.drugpo.2014.01.001. View

18.

van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf D . Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 2014; 109(7):1101-9. DOI: 10.1111/add.12508. View

19.

Freeman T, Morgan C, Hindocha C, Schafer G, Das R, Curran H . Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction. 2014; 109(10):1686-94. DOI: 10.1111/add.12634. View

20.

Zamengo L, Frison G, Bettin C, Sciarrone R . Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. Toxicol Lett. 2014; 229(1):220-8. DOI: 10.1016/j.toxlet.2014.06.012. View